Skip to content
TickerMagic

Kilitch Drugs (India) Limited

KILITCHNSEHealthcare
₹236.95
+6.83 (+2.97%) · EOD 2026-11-20

Our verdict

Strong Buy

Valuation (99/100) does the heavy lifting; quality (65/100) is the drag.

Buy zoneHealth B
Quality 65Momentum 95Value 99Trend 88The Spark ↓

Our fair value

Undervalued by 36%
₹321.53up 35.70%
Price ₹237Range ₹118 – ₹389

Buy-below (20% margin of safety): ₹257.22

The bottom line

Our blended model reads Kilitch Drugs (India) Limited as a Strong Buy at 86/100. At ₹236.95 it trades below our blended DCF and relative-multiples fair value of ₹321.53, about 36% upside to that estimate — we read it as undervalued by 36%. On 21.4x trailing earnings it sits cheaper than the Healthcare median of about 37.4x. The price is about 9% below its 52-week high of ₹260.7 and 90% above the low of ₹124.45. Financial health scores 65/100, with a Piotroski F-score of 1/9. It clears 9 of 12 investability checks, with durability 65, valuation 97 and momentum 95 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹321.53up 35.70%
Undervalued by 36%
Price ₹236.95Range ₹118.48–₹388.64
DCF + relative blendhigh confidence

With a 20% margin of safety, our buy-below price is ₹257.22.

1-year price

EOD · 2026-11-20
1D
up 2.97%
1W
up 18.11%
1M
up 8.21%
3M
up 44.52%
6M
up 35.89%
1Y
—

52-week range

-9.11% from the 52-week high.

Trend check
Above 50-DMA₹214Above 200-DMA₹180

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Strong Buy86
B
Financial health 65/100
From leverage, liquidity & coverage ratios

Piotroski F-score 1/9 — quality of earnings & balance sheet.

Our scores

Durability65
Valuation97
Momentum95

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 9 of 12 checks
Each check screens one fundamentals, valuation or trend signal.
  • Fail: ROE above 15%: 12.4%
  • Pass: Low debt (D/E < 0.5): 0.32x
  • Fail: Positive free cash flow
  • Pass: Revenue growth > 10%: 46%
  • Pass: Earnings growing: 27%
  • Pass: Net margin ≥ 10%: 12.8%
  • Pass: Current ratio > 1.5: 1.83
  • Pass: Below our fair value
  • Pass: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Pass: Above 50-day average
  • No data: Positive 1-year return
  • No data: Altman Z in safe zone
  • Fail: Piotroski ≥ 7: 1/9

Shareholding

  • Promoter72.2%
  • Institutions0.0%
  • Public & other27.8%

Promoter holding via insider stake; institutional via reported holdings.

Superstar investors in Kilitch Drugs (India) Limited

Named in the company's June 2026 shareholding filing with the exchanges.

All superstar portfolios →

Key fundamentals

Market cap
₹667 Cr
P/E ratio
21.4
P/B ratio
2.34
EPS (TTM)
₹8.91
ROE
12.4%
Debt / Equity
0.32x
Profit margin
12.8%
Free cash flow
₹-89 Cr
52-week high
₹260.7
-9.11% from high
52-week low
₹124.45
Dividend yield
—
Beta
0.17
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Lightly leveraged balance sheet.

Opportunities

  • Earnings growing (27% YoY).
  • Revenue growing (46% YoY).
  • Trading in our value buy zone versus sector peers.
  • Trades ~36% below our estimated fair value.

Bear case

Weaknesses

  • Weak Piotroski score (1/9).

About Kilitch Drugs (India) Limited

Kilitch Drugs (India) Limited develops and operates a pharmaceutical business in India and internationally. The company manufactures parenteral, nasal, and topical products, including liquid ampoules, vials, dry powder injectables, and metered nasal drops for therapeutic areas including gastroenterology, anti-inflammatory, anticonvulsant, anti-malarial, antibacterial, anti-hypertensive, and anti-infective applications.

Kilitch Drugs (India) Limited — frequently asked questions

Is Kilitch Drugs (India) Limited a buy, hold or sell?

TickerMagic currently rates Kilitch Drugs (India) Limited (KILITCH) a Strong Buy, based on a blended score of 86/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Kilitch Drugs (India) Limited's fair value?

Our blended DCF and relative-valuation model estimates Kilitch Drugs (India) Limited's fair value at about ₹321.53, versus a current price of ₹236.95 — roughly 36% upside. On that basis the stock looks undervalued by 36%.

Is Kilitch Drugs (India) Limited financially healthy?

Kilitch Drugs (India) Limited scores 65/100 on our financial-health model, with a Piotroski F-score of 1/9.

How has Kilitch Drugs (India) Limited's share price performed?

Kilitch Drugs (India) Limited is up 45% over three months, and last traded at ₹236.95. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.